Document is current
Any future updates will be listed below
-
Authors
Thorel, Lucie
Dolivet, Enora
Morice, Pierre-Marie
Florent, Romane
Divoux, Jordane
Perréard, Marion
Lecouflet, Lucie
Desmartin, Guillaume
Alagama, Chloé Marde
Giffard, Florence
Leconte, Alexandra
Lequesne, Justine
Clarisse, Bénédicte
Briand, Mélanie
Traoré, Alimatou
Villenet, Céline
Meneboo, Jean-Pascal
Babin, Guillaume
Gaichies, Léopold
Martin-Françoise, Sandrine
Brun, Jean-François Le
Rouzier, Roman
Brotin, Emilie
Denoyelle, Christophe
Vigneron, Nicolas
Leman, Raphaël
Vaur, Dominique
Castera, Laurent
Blanc-Fournier, Cécile
Elie, Nicolas
Plancoulaine, Benoit
Joly, Florence
Meryet-Figuière, Matthieu
Figeac, Martin
Weiswald, Louis-Bastien
Poulain, Laurent
-
Funding
Funding for this research was provided by:
Cancéropôle Nord-Ouest (ORGRAFT)
Fondation de l’Avenir (AP-RM-19-020)
Fondation ARC pour la Recherche sur le Cancer (PJA20191209649)
Région Normandie (ORGATHEREX)
Ligue Contre le Cancer (ORGAPRED)
- License Information
-
More Information
Article History
Received: 1 April 2025
Accepted: 3 September 2025
First Online: 7 October 2025
Declarations
:
: Informed consent forms were signed by all patients and were obtained either by the Biological Resources Center ‘OvaRessources’, which has received NF 96 900 accreditation (N° 2016/72860.1) or in the context of the ‘OVAREX’ clinical trial (N°ID-RCB: 2018-A02152-53, NCT03831230) [], in accordance with ethical committee and European law.
: Not applicable.
: The authors declare no competing interests.
